Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Seaforth ...

While your question wasn't directed at me, I'll provide a potential answer. There is the obvious of reducing the OS, even at relatively small amounts, which every little bit helps. However, here's another way to look at it:



RG is targeting an M&A by the end of the year.

He's stated he expects to use cash AND stock to complete the deal.

He also has stated he finds the current pricing attractive.

In stating that, he implies that he expects future pricing to be LESS attractive for buyback purposes, and therefore, MORE attractive with respect to share values.

Therefore, $3M cash he might spend to day to buyback shares, by his analysis could well be worth $6M or more in shares that he might use in November to consumate and M&A deal.

So perhaps that's one objective to keep in mind.

Share
New Message
Please login to post a reply